Table 1 (abstract P239). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
| Â | Non-TNFi (n=7) | TNFi (n=23) |
|---|---|---|
Age at II bDMARDs, years | 10.7 ± 4.9 (5.3-19.4) | 10.9 ± 5.2 (0.2-19) |
Clinical inactive disease | 4 (57%) | 14 (61%) |
II bDMARDs discontinuations | 3 (43%) | 13 (56%) |
Duration of II bDMARDs, years | 2.7 ± 3.1 (0.15-8.8) | 2.6 ± 2.3 (0.2-9) |